Objective: LMNB1-related autosomal dominant leukodystrophy is caused by an overexpression of the protein lamin B1, usually due to a duplication of the LMNB1 gene.
| INTRODUC TI ON
LMNB1-related autosomal dominant leukodystrophy (ADLD) is an adult-onset disease in which the first symptoms manifest in the 5 th to 6 th decade. 1,2 The original report described the disease as a "hereditary adult-onset leukodystrophy simulating chronic progressive multiple sclerosis", 1 and in some later papers it has been called adultonset ADLD with autonomic symptoms. 3, 4 The disease is caused
by an increased expression of the nuclear protein lamin B1, due to either a duplication of the LMNB1 gene (OMIM #150340) [5] [6] [7] or enhancer adoption due to a genomic deletion. 8 The increased levels of lamin B1 seem to cause age-dependent inhibition of lipid synthesis in oligodendrocytes, resulting in demyelination. 9 Lamin B1 levels also modulate the development of neurons and astroglial-like cells. [10] [11] [12] [13] Patients most often present with autonomic dysfunction, later progressing with symptoms from cerebellum and spinal tracts, pseudobulbar signs, cognitive decline, and finally death, usually approximately two decades after symptom onset. 1, 2, 6 All patients seem to develop bladder dysfunction which is usually the first symptom.
In about three quarters of the patients, orthostatic hypotension has been found. 2 From the cardiovascular point of view, the impairment of the autonomic control is limited to the sympathetic system.
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Typical magnetic resonance imaging (MRI) findings in the brain
include early involvement of the cerebellar peduncles and corticospinal tracts progressing to symmetrical extensive cerebral white matter changes. The periventricular area is typically less affected.
The spinal cord is abnormally thin with pathological signal intensity in the white matter. These findings, together with clinical symptoms of myelopathy with autonomic dysfunction, are sufficiently specific to enable the diagnosis, which can be confirmed by genetic analysis.
2,6
On histological examinations, myelin appears rarefied and vacuolated. There is no significant pathology in the cerebral cortex, while in the cerebellum the number of Purkinje cells is reduced and the number of Bergmann astroglial cells slightly increased. 3 In studies using magnetic resonance spectroscopy, to investigate the metabolism in the white matter in patients with LMNB1-related ADLD, lactate has been found in the cerebrospinal fluid but not in the brain parenchyma. Further, metabolite levels in the parenchyma have been found to be normal when quantified using creatine as an internal reference. 15, 16 There are no previous studies measuring glucose metabolism in LMNB1-related ADLD.
The aim of this study was to investigate glucose metabolism in the brain in LMNB1-related ADLD using 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET).
| MATERIAL S AND ME THODS
| Subjects
Eight patients, aged 48-64 years, from two unrelated families seg- The original datasets were not available. Original clinical quantitative analysis used in the study.
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The blood sampling failed. A low dose CT was performed in the same session for attenuation correction.
| FDG-PET technique
| Data analysis
In Patient 7, blood sampling failed and no quantitative data could be obtained. In Patients 1, 3-6, and 8 and in the controls, quantitative glucose metabolism images were produced by the method described by Patlak. 18 The data were post-processed using the software PVElab 19 and automatically divided into 46 volumes of interest (VOIs) using a probability-based method. 20 Forty-four of these 46
VOIs were bilateral and from these an average value of the two sides 
| Statistical analysis
Statistical analyses were performed using the free software R.
Welch′s unequal variance t tests were performed to find statistically significant differences in levels of FDG uptake and glucose metabolism. No correction for multiple comparisons was performed but the brain regions were tested separately.
The study was approved by the regional ethics committee and performed in accord with the ethical standards of the Declaration of Helsinki. Subjects gave informed consent before participating in the study.
F I G U R E 2 Glucose metabolism vs age by region of interest in patients (triangles) and healthy controls (dots) as analyzed with PVElab 
| Quantitative analysis in patient 2
| Semiquantitative glucose metabolism of Patients 1 and 3-8 analyzed with CortexID
Regions of interest with statistically decreased or increased FDG uptake compared to the general FDG uptake (z-scores <−2 or > 2, respectively) are presented in Table 2 . In Patients 1, 5, 6, and 8 a higher metabolism was found in parts of the temporal lobes compared to the global metabolism. In Patients 1 and 7, a decreased metabolism was seen in the cerebellum.
| D ISCUSS I ON
In this study with FDG-PET, we found a reduced mean glucose me- Four of seven patients analyzed with a semiquantitative method had a higher relative glucose metabolism in the temporal lobes compared to global metabolism. However, since none of the patients showed an increased metabolism in the quantitative analysis, we interpret these findings as "pseudo-increases" related to a globally reduced metabolism. This is of importance for interpreting semiquantitative values in relation to the choice of reference region. The relatively higher temporal metabolism is in line with the evolution of MRI findings since the white matter of the temporal lobes is the last white matter area to be affected in LMNB1-related ADLD.
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Previously, 10 studies or case reports describing FDG-PET findings in a total of 21 patients with leukodystrophies have been reported. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Seventeen of these patients had X-linked adrenoleukodystrophy (X-ALD), including adrenomyeloneuropathy (AMN). As glucose metabolism is physiologically much higher in grey than in white matter, metabolic changes on FDG-PET could be mainly found in grey matter, whereas abnormal FDG uptake in white matter was only described in three of those 21 patients. 23, 24, 26 We found a significantly abnormal uptake in two of our eight patients in global white matter but there was no significant difference between the patients and the controls as groups. Brain regions with reduced glucose metabolism were found in all leukodystrophy patients both in literature and in our study. In X-ADL, increased metabolic activity was also detected. 24, 31 In addition to the cortical areas overlying pathological white matter, analysis of brain glucose metabolism could reveal abnormalities in regions without signal changes on MRI 22, 32 and, in AMN patients, even with a totally normal MRI. 29, 31 In contrast, no abnormal glucose metabolism could be found in the vicinity of some white matter changes on MRI in 1 patient. 31 In the only previous multi-subject PET study on leukodystrophy, 31 a characteristic pattern was found for X-ALD:
hypermetabolism in the frontal areas and anterior cingulate cortex and hypometabolism in the temporal areas and cerebellum.
The physiopathological basis of the reduced cortical glucose metabolism in leukodystrophies is not known but it has been hypothesized that hypometabolism in X-ADL is not due to true pathological changes in these areas but to altered connectivity, deafferentation, in white matter. 30, 31 This hypothesis was supported by the lack of cortical atrophy in affected locales on MRI.
Postmortem studies of X-ALD have also not shown any atrophy.
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The increased levels of lamin B1 do not only affect oligodendrocytes and, secondarily to that, myelin 9 but also neuronal development. [10] [11] [12] However, in histopathological studies of patients with LMNB1-related ADLD, the cerebral cortex has been normal. 3, 33 Therefore, we assume that the globally decreased glucose metab- It may also correspond to the active neuroinflammatory process in X-ALD.
34
The age matching between the patients and control group is not optimal in the quantitative part of this study. For ethical reasons, we could not recruit age-matched controls for a PET study. However, as cerebral glucose metabolism decreases with age 35 and the patients were on average 10 years younger than the controls, we believe we can trust the findings of decreased glucose metabolism in the patients. Our most severely affected patient was 7 years younger than the average age of the controls. 
TA B L E 2
Regions with glucose metabolism lower or higher than globally in the brain in the semiquantitative analysis with the CortexID software suite
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